In Brief: Pharmacia Biotech
This article was originally published in The Gray Sheet
Executive SummaryPharmacia Biotech: Gains non-exclusive worldwide license to Hoffmann-La Roche's polymerase chain reaction (PCR) technology for research uses. The license gives Pharmacia Biotech "the rights to manufacture and sell Taq DNA polymerase and other thermostable enzymes" under development for use in performing PCR, and also allows the firm to develop Ready-To-Go PCR beads, the firm states...
You may also be interested in...
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.
Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.